Diagnostics

Predicine Expands to Europe with the recently launched CE-Marked cfDNA Assay PredicineCARE™ for Genomic Profiling in Blood and Urine

SILICON VALLEY, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Predicine, Inc., a global molecular insights company, has launched its CE-marked...

Todos Medical Announces First Two Contracts for PCR-based MonkeyPox Testing at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics

New York, NY, and Tel Aviv, ISRAEL, Aug. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive...

Data Results Published in American Journal of Managed Care demonstrate adoption and clinical utility of KidneyIntelX™ with Primary Care Physicians

98% of 401 Primary Care Physicians confirmed KidneyIntelX has value as a risk decision tool in their adult patients with...

Attralus Receives U.S. FDA Orphan Drug Designation for AT-01 (Iodine (I-124) Evuzamitide), an Investigational Diagnostic for the Management of Transthyretin Amyloidosis

SAN FRANCISCO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve...

Todos Medical Announces First Long COVID Clinic Laboratory Services Agreement for Long COVID Panel Biomarker Partnership with Amerimmune Diagnostics

RTHM collaborating on Tollovid™ 3CL inhibitor immune support supplement case studiesTollovid biomarker data to support potential structure-function claims in Long...

Syapse Announces $35 Million Growth Investment with Innovatus Capital Partners to Expand Delivery of Real-World Evidence Through Syapse’s Learning Health Network

SAN FRANCISCO and NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing...

OpGen Subsidiary Ares Genetics GmbH Enters into Collaboration Agreement with the Belgian National Reference Centre for Invasive S. pneumoniae at UZ Leuven

Collaborators aim to develop and evaluate computation tools, including predictive models for whole genome sequencing-based antibiotic susceptibility testing (wgsAST)Ares plans...

CHMP recommends EU approval of Roche’s Vabysmo, the first bispecific antibody for the eye, for two leading causes of vision loss

Vabysmo (faricimab) simultaneously targets and inhibits two disease pathways that drive neovascular or “wet” age-related macular degeneration (nAMD) and diabetic...

error: Content is protected !!